Source:http://linkedlifedata.com/resource/pubmed/id/16927289
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2006-8-28
|
| pubmed:abstractText |
Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24-49] vs. 47 [24-67] or 44 [18-73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1-8.7] vs. 6.5 [<3.7-8.7] or 6.5 [<3.7-8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003). HBeAg (hazard ratio 2.1 [95% confidence interval 1.53-2.92], P < 0.001) and genotype A (2.78 [1.08-7.12], P = 0.034) enhanced the emergence of YMDD mutants by the Cox proportional hazard model. The risk for breakthrough hepatitis was increased by the baseline alanine aminotransferase level <500 IU/L (2.56 [1.82-5.50], P = 0.018), HBeAg (2.11 [1.40-3.16], P < 0.001), cirrhosis (1.92 [1.24-2.97], P = 0.004) and HBV DNA > or =8.0 LGE/ml (1.57 [1.04-2.36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long-term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0146-6615
|
| pubmed:author |
pubmed-author:AkutaNorioN,
pubmed-author:AraseYasujiY,
pubmed-author:HosakaTetsuyaT,
pubmed-author:IkedaKenjiK,
pubmed-author:IwasakiSatomiS,
pubmed-author:KobayashiMarikoM,
pubmed-author:KobayashiMasahiroM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:MiyakawaYuzoY,
pubmed-author:SatoJunkoJ,
pubmed-author:SezakiHitomiH,
pubmed-author:SuzukiFumitakaF,
pubmed-author:SuzukiYoshiyukiY,
pubmed-author:WatahikiSachiyoS
|
| pubmed:issnType |
Print
|
| pubmed:volume |
78
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1276-83
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16927289-Administration, Oral,
pubmed-meshheading:16927289-Adolescent,
pubmed-meshheading:16927289-Adult,
pubmed-meshheading:16927289-Aged,
pubmed-meshheading:16927289-Disease Progression,
pubmed-meshheading:16927289-Female,
pubmed-meshheading:16927289-Genetic Markers,
pubmed-meshheading:16927289-Genome, Viral,
pubmed-meshheading:16927289-Genotype,
pubmed-meshheading:16927289-Hepatitis B, Chronic,
pubmed-meshheading:16927289-Hepatitis B virus,
pubmed-meshheading:16927289-Hospitals, Urban,
pubmed-meshheading:16927289-Humans,
pubmed-meshheading:16927289-Lamivudine,
pubmed-meshheading:16927289-Male,
pubmed-meshheading:16927289-Middle Aged,
pubmed-meshheading:16927289-Mutation,
pubmed-meshheading:16927289-Proportional Hazards Models,
pubmed-meshheading:16927289-Reverse Transcriptase Inhibitors,
pubmed-meshheading:16927289-Time Factors,
pubmed-meshheading:16927289-Tokyo,
pubmed-meshheading:16927289-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
|
| pubmed:affiliation |
Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan. vj7m-kbys@asahi-net.or.jp
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|